ClinicalTrials.gg

Program

4-MUST

Its studies are led by Valenta Pharm JSC.

Furthest: phase 3, since May 12, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSC33 open or runningphase 3since May 12, 2026Feb 17, 2025Dec 31, 2026phase 2 · NCT06842966

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2025First study: phase 2 study in Biliary DyskinesiaFirst studyNCT06842966 · 300 planned · Russia
  2. May 12, 2026Phase 3 study in Biliary DyskinesiaPhase 3 reachedNCT07595003 · 300 planned · Russia
  3. May 12, 2026Phase 1 study in Biliary DyskinesiaNCT07594977 · 45 planned · Russia

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Biliary DyskinesiaNCT06842966
  2. Jun 30, 2027Primary completion: phase 1 study in Biliary DyskinesiaNCT07594977
  3. Dec 31, 2027Primary completion: phase 3 study in Biliary DyskinesiaNCT07595003

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07595003Biliary Dyskinesia · Russia3RecruitingDec 31, 2027300
NCT07594977Biliary Dyskinesia · Russia1RecruitingJun 30, 202745
NCT06842966Biliary Dyskinesia · Russia2RecruitingDec 31, 2026300

How it is read

Names in the registry

  • “4-MUST”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.